X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
SLS009 (GFH009) is a small molecule, highly selective CDK9 inhibitor, demostrated anti-tumor activity in the study being investigated for the treatment of relapsed/refractory acute myeloid leukemia.
Lead Product(s): SLS009,Venetoclax,Azacitidine
Therapeutic Area: Oncology Product Name: GFH009
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 26, 2024
Details:
The net proceeds will be used in the clinical development of SLS-001 (galinpepimut-S) in combination with Sargramostim. Currently, it is being evaluated in Phase III clinical trial studies for the treatment of Acute Myeloid Leukemia.
Lead Product(s): Galinpepimut-S,Sargramostim
Therapeutic Area: Oncology Product Name: SLS-001
Highest Development Status: Phase IIIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Alliance Global Partners
Deal Size: $20.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering March 19, 2024
Details:
The net proceeds will be used in the clinical development of SLS-001 (galinpepimut-S) in combination with Sargramostim. Currently, it is being evaluated in Phase III clinical trial studies for the treatment of Acute Myeloid Leukemia.
Lead Product(s): Galinpepimut-S,Sargramostim
Therapeutic Area: Oncology Product Name: SLS-001
Highest Development Status: Phase IIIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Alliance Global Partners
Deal Size: $20.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering March 15, 2024
Details:
GFH009 (SLS009) is a novel and highly selective CDK9 inhibitor, which is under phase 1/2 clinical development for the treatment of relapsed/refractory (r/r) acute myeloid leukemia (AML).
Lead Product(s): SLS009
Therapeutic Area: Oncology Product Name: GFH009
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 09, 2024
Details:
The net proceeds will fund ongoing clinical development of existing product candidates, including SLS-001 (galinpepimut-s), an immunotherapeutic which targets the WT1 protein, present and over-expressed in an array of hematological malignancies and solid tumors.
Lead Product(s): Galinpepimut-s,Sargramostim
Therapeutic Area: Oncology Product Name: SLS-001
Highest Development Status: Phase IIIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Alliance Global Partners
Deal Size: $9.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering January 04, 2024
Details:
The net proceeds will fund ongoing clinical development of existing product candidates, including SLS-001 (galinpepimut-s), an immunotherapeutic which targets the WT1 protein, present and over-expressed in an array of hematological malignancies and solid tumors.
Lead Product(s): Galinpepimut-s,Sargramostim
Therapeutic Area: Oncology Product Name: SLS-001
Highest Development Status: Phase IIIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Alliance Global Partners
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Public Offering January 03, 2024
Details:
SLS-001 (galinpepimut-S) is a WT1 inhibitor vaccine candidate which is under phase 1 clinical development in combination with Nivolumab & Sargramostim for the treatment of refractory/relapsed malignant pleural mesothelioma.
Lead Product(s): Galinpepimut-S,Nivolumab,Sargramostim
Therapeutic Area: Oncology Product Name: SLS-001
Highest Development Status: Phase IProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 27, 2023
Details:
GFH009 (SLS009) is a novel and highly selective CDK9 inhibitor, which is under phase 1/2 clinical development for the treatment of relapsed or refractory peripheral t-cell lymphoma.
Lead Product(s): SLS009
Therapeutic Area: Oncology Product Name: GFH009
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 21, 2023
Details:
SLS009 is a novel and highly selective CDK9 inhibitor, which is being evaluated in combination with venetoclax and azacitidine in patients with relapsed/refractory (r/r) acute myeloid leukemia (AML) who did not respond or stopped responding to venetoclax-based therapies.
Lead Product(s): SLS009
Therapeutic Area: Oncology Product Name: GFH009
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 14, 2023
Details:
SLS-001 (galinpepimut-s) is an immunotherapeutic which targets the Wilms Tumor 1. It is being evaluated in phase 3 clinical trials for the treatment of Acute Myeloid Leukemia.
Lead Product(s): Galinpepimut-S,Sargramostim
Therapeutic Area: Oncology Product Name: SLS-001
Highest Development Status: Phase IIIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 04, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
